secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001140361-24-028106
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre subsidiary receives China NMPA IND approval for F230 in pulmonary arterial hypertension
--------------------------------------------------------------------------------

- IND approved by CDE of China's NMPA for F230 tablets, a selective endothelin receptor antagonist for PAH.
- F230 originally licensed from Eisai through Gyre's indirect stockholder GNI Group Ltd.
- Preclinical data showed statistically significant reductions in mean pulmonary artery pressure and right ventricular systolic pressure.
- CEO Han Ying stated commitment to advancing F230 through clinical development for PAH; other indications also being explored.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124028106/0001140361-24-028106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036124028106/ef20030279-8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-028106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer